DOT or SAT for Rifampicin-Resistant Tuberculosis? A Non-Randomized Comparison in a High HIV-Prevalence Setting

Hdl Handle:
http://hdl.handle.net/10144/618932
Title:
DOT or SAT for Rifampicin-Resistant Tuberculosis? A Non-Randomized Comparison in a High HIV-Prevalence Setting
Authors:
Mohr, E; Daniels, J; Beko, B; Isaakidis, P; Cox, V; Steele, S; Muller, O; Snyman, L; De Azevedo, V; Shroufi, A; Trivino Duran, L; Hughes, J
Journal:
PLoS ONE
Abstract:
Daily directly-observed therapy (DOT) is recommended for rifampicin-resistant tuberculosis (RR-TB) patients throughout treatment. We assessed the impact of self-administered treatment (SAT) in a South African township with high rates of RR-TB and HIV.
Publisher:
Public Library of Science
Issue Date:
18-May-2017
URI:
http://hdl.handle.net/10144/618932
DOI:
10.1371/journal.pone.0178054
PubMed ID:
28542441
Submitted date:
2017-05-30
Language:
en
ISSN:
1932-6203
Appears in Collections:
TB

Full metadata record

DC FieldValue Language
dc.contributor.authorMohr, Een
dc.contributor.authorDaniels, Jen
dc.contributor.authorBeko, Ben
dc.contributor.authorIsaakidis, Pen
dc.contributor.authorCox, Ven
dc.contributor.authorSteele, Sen
dc.contributor.authorMuller, Oen
dc.contributor.authorSnyman, Len
dc.contributor.authorDe Azevedo, Ven
dc.contributor.authorShroufi, Aen
dc.contributor.authorTrivino Duran, Len
dc.contributor.authorHughes, Jen
dc.date.accessioned2017-06-04T16:10:46Z-
dc.date.available2017-06-04T16:10:46Z-
dc.date.issued2017-05-18-
dc.date.submitted2017-05-30-
dc.identifier.citationDOT or SAT for Rifampicin-Resistant Tuberculosis? A Non-Randomized Comparison in a High HIV-Prevalence Setting. 2017, 12 (5):e0178054 PLoS ONEen
dc.identifier.issn1932-6203-
dc.identifier.pmid28542441-
dc.identifier.doi10.1371/journal.pone.0178054-
dc.identifier.urihttp://hdl.handle.net/10144/618932-
dc.description.abstractDaily directly-observed therapy (DOT) is recommended for rifampicin-resistant tuberculosis (RR-TB) patients throughout treatment. We assessed the impact of self-administered treatment (SAT) in a South African township with high rates of RR-TB and HIV.en
dc.language.isoenen
dc.publisherPublic Library of Scienceen
dc.rightsPublished by Public Library of Science, [url]http://www.plosone.org/[/url] Archived on this site by Open Access permissionen
dc.titleDOT or SAT for Rifampicin-Resistant Tuberculosis? A Non-Randomized Comparison in a High HIV-Prevalence Settingen
dc.identifier.journalPLoS ONEen

Related articles on PubMed

All Items in MSF are protected by copyright, with all rights reserved, unless otherwise indicated.